Teladoc price target lowered to $7 from $8.50 at Barclays

Barclays lowered the firm’s price target on Teladoc (TDOC) to $7 from $8.50 and keeps an Equal Weight rating on the shares after meeting with management. There is reason for optimism in parts of the business like International and on the insured side of BetterHelp, but the company is transitioning its model in a competitive segment of the market, the analyst tells investors in a research note.